Established in 1997, One Nucleus is a not-for-profit, membership organisation located in Cambridge and London.

One Nucleus have over 500 members across fields such as pharmaceuticals, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’s mission is to maximise the global competitiveness of their members. For their science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For their business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

Responding to the changing needs of their members and the life science landscape, One Nucleus is delighted to announce the evolution of its traditional Cambridge BioPartnering Exchange to bring you the next generation in life science conferences.

Having recognised the increasingly complex relationships between medical product developers, regulators and payers, One Nucleus launched the Life Science Leadership Series – a series of 1-day events that have a therapeutic and/or technology area focus in 2011.  The Cambridge Life Science Leadership Series deliver a cost-effective forum to showcase what is driving commercial deals, value creation, platform technologies and Government support in specific focussed areas.

This event will specifically focus on the Healthcare Technologies sector.

The aim is to complement the global biopartnering conferences, facilitating delegates in sharing knowledge and engaging thought-leadership through challenging each other towards best practice in the efficient development of new treatments and technologies.

This event will:

1. Provide a first class programme that informs all delegates and sparks debate collectively about how we could be doing things better in terms of development plans that meet regulator, patient and commercial needs

2. Bring together the discovery and development pipeline from bench to patient, so including advances in drug delivery, disease monitoring, biomarkers and the core R&D activities

3. Provide effective networking and 1-2-1 partnering: due to the maximum 200 delegates